


Urgent Care Clinical Guideline




Exclusion Criteria

Diagnosis of:

- Bronchiolitis
- Asthma exacerbation
- Pneumonia
- Croup
- · Pertussis or suspected pertussis
- Suspicion for foreign object in airway

Provide age-appropriate symptomatic care

- Antipyretics/analgesic administration (See annotation A for dosing recommendations)
- Saline irrigation (See annotation B)
- Adequate hydration (Warm fluid ingestion soothes respiratory mucosa, increases flow of nasal mucus, and loosens respiratory secretions)
- · Cool mist humidified air
- Rest
- Elevation of head while sleeping
- Honey (if age > 12 months) in warm liquids to drink
 - 1 to 5 years old: 1/2 teaspoon
 - 6 to 11 years old: 1 teaspoon
 - ≥ 12 years old: 2 teaspoons
- Cough lozenges or hard candy if > 6 years of age
- Several common products are not recommended (see annotation C)



care only

- · Cough lozenges or hard candy > 6 years
- Other age-appropriate supportive cares

May use OTC cold medicines for temporary relief of symptoms

(see annotation C)

- Oral decongestants
 - o Pseudoephedrine IR: 60 mg every 4-6 hrs; MAX daily dose 240 mg/day
- Nasal decongestants: limit 3 days due to rebound congestion and remind families to administer sitting upright
 - Oxymetazoline 0.05%: 2 sprays in each nostril twice daily; MAX 2 doses daily
 - o Phenylephrine 0.25% -1%: 1-3 sprays in each nostril every 4 hours as needed
- FYI: Generic products tend to be less expensive; all ingredients must be taken into consideration



Clinical Guideline

Annotations

A. Antipyretic dosing recommendations

- Acetaminophen 10- 15mg /kg every 4-6 hours as needed, do not exceed 5 doses within 24 hours.
- Ibuprofen 10 mg/kg every 6-8 hours as needed (≥ 6 months of age)

B. Saline irrigation

- Flushes nasal secretions, increases mucociliary clearance of secretions, vasoconstricts mucosa.
- OTC saline irrigation spray and/or saline nose drops available. (Kelly, 2004)
- Mix 1 teaspoon of salt in 8 ounces of lukewarm distilled or boiled water. Salt should also be iodide-free like pickling or canning salt.

C. Common products not recommended

Advice for parents who choose to use OTC products despite CW recommendation against use

- Medications are unlikely to work
- Use single-ingredient preparations; combination products may be dangerous if similar medication is given to a child inadvertently in another product
- Products deemed to be "natural" are not well studied difficult to know how much is absorbed and which side effects may result

• External rubs (e.g., Vaporub, Babyrub)

- o Parental report of cough severity improvement has been reported, however parental report is often unreliable compared with objective data.
- Exposure to camphor, an ingredient in many rubs, is a concern. Although most exposures result in minor or no toxicity, refractory seizures can occur due to the high absorption rate of camphor. (Yin, 2021)
- o Rubs that do not contain camphor typically contain eucalyptus, lavender, or rosemary, which are known to cause GI or skin irritation.

Antihistamines (e.g., Benadryl, diphenhydramine, Vistaril, hydroxyzine,)

- o Infants & Children: sedation may be the only beneficial effect; ineffective in relieving cold symptoms.
- Adolescents & Adults: When used alone not been shown to offer clinically significant benefits but may be helpful in combination with decongestants.
- o Use with caution in children with asthma as they thicken secretions and make them harder to clear.
- Side effects: paradoxical excitability, respiratory depression, cardiac arrhythmias, hallucinations, dizziness, blurred vision, urinary retention, or dystonic reactions
- 1st generation (diphenhydramine) have increased risk of overdose and side effects due to ability to cross blood brain barrier.

• **Decongestants** (E.g., Pseudoephedrine, Phenylephrine, Oxymetazoline)

- Approved for use in children ≥ 6 years, but the AAP recommends use only for children ≥ 12 years
 - Not shown to be effective in children under 12 years of age.
 - Anecdotal reports of serious toxicity in young children using these products.
 - Use in adolescents and adults for a few days is reasonable and consistent with usual practice.
- o Moderate short-term benefit reported in adolescents and adults
- Decongestants are sympathomimetic agents that decrease nasal congestion by causing vasoconstriction, reducing blood volume and swelling in the nasal mucosa and paranasal sinuses.
- Side effects of systemic decongestants include irritability, agitation, sleeplessness, anorexia, nausea, vomiting, cardiac arrhythmias, palpitations, seizures, and dystonic reactions.
- Topical preparations
 - Never use in infants
 - Can cause significant rebound congestion and prolonged use of topical decongestants can cause rhinitis medicamentosa, a chronic inflammatory rhinitis. Moderate short-term benefit reported in adolescents and adults – use sparingly and no longer than 72 hours.



Clinical Guideline

Annotations (continued)

- Antitussives (e.g., Dextromethorphan, Codeine, Hydrocodone)
 - Lack of evidence for antitussive effects found in multiple studies/reviews.
 - o Potential risks: respiratory suppression and abuse of controlled substances. May make it harder to expel mucous use cautiously in children with asthma
 - o AAP does not recommend dextromethorphan in children despite labeling for use in children ≥ 4 years old
 - o Cough and cold medicine containing codeine is limited to use in only those 18 years and older
- Expectorants (e.g., Guaifenesin) Lack of evidence to support effects
- Combination products (e.g., Robitussin®, Advil® Multi-symptom Cold and Flu, Theraflu®)
 - o Increased risk of overdose and harmful side effects compared to single use products
 - Products containing antihistamine and decongestant may aid in some symptom relief; may aid sleep in younger children similar to 1st generation antihistamines alone; may decrease nasal symptoms in adolescents & adults.
 - Products containing expectorant and cough suppressant would result in thinned secretions that could not be expelled because of cough suppression
 - AAP recommends decongestants only for children ≥12 years old.



Clinical Guideline

References

De Sutter, A.I., Saraswat. A., Van Driel, M.L. (2015). Antihistamines for the common cold. Cochrane Database Systematic Review

Kelly, L. (2004). Pediatric cough and cold preparations. Pediatrics in Review, 25, 115-123.

Kim, S.Y., Chang, Y.J., Cho H.M., Hwang, Y.W., Moon, Y.S. (2015). Non-steroidal antiinflammatory drugs for the common cold. Cochrane Database Systematic Review

Lowry, J.A., & Leeder, J.S. (2015). Over-the-counter medications: Update on cough and cold preparations. Pediatrics in Review, 36, 286-298.

Oduwole, O., Udoh, E.E., Oyo-Ita, A., Meremikwu, M.M. (2018). Honey for acute cough in children. Cochrane Database Systematic Review

Pappas, D. E. (2025). The common cold in children: Management and prevention. UpToDate.

Retrieved from http://www.uptodate.com

Pappas, D. E., & Hendley, O. (2011). The common cold and decongestant therapy. Pediatrics in Review, 32, 47-55.

Simasek, M., & Blandino, D. (2007). Treatment of the common cold. American Family Physician. 75, 515-522.

Smith, M., & Feldman, W. (1993). Over the counter cold medications: A critical review of clinical trials between 1950 and 1991. JAMA, 269, 2258-2263.

Tobias, J. D., Green, T. P., & Cote, C. J. (2016). Codeine: Time to say no. Pediatrics, 138(4)

US Food and Drug Administration. (2018). FDA drug safety communication: FDA requires labeling changes for prescription opioid cough and cold medicines to limit their use to adults 18 years and older. Retrieved from: https://www.fda.gov/Drugs/DrugSafety/ucm590435.htm

Yin, S. (2021). Camphor poisoning in children. UpToDate. Retrieved from http://www.uptodate.com

Yin, S. (2024). Over-the-counter cough and cold preparations: Approach to pediatric poisoning.

UpToDate. Retrieved from http://www.uptodate.com

Medication information provided by Meghan Wagner, Pharmacist, and Katie Ray, Pharmacist, CW Pharmacy (personal communication, October, 2025).

Treatment information provided by Amy Drendel, DO, Medical Director, CW Emergency Department (personal communication, July, 2018).

Treatment information provided by Chris Schwake, MD, Interim Medical Director, Pediatrician, CMG, (personal communication, April, 2022).



Clinical Guideline

Please contact childrenswi.org for questions or comments.

Original: 07/2015

Reviewed 07/2018, 04/2022 Current revision date: 11/2025

Approved by: UC Physician Lead for Quality and Safety, Medical Director

Date November 17, 2025

Revision Authors/Stakeholders:

Department	Name, credentials
Urgent Care , Owner	Rachel Lucas, DO
Medical Director, Urgent Care	Amy Romashko, MD
Pharmacist	Megan Wagner
Pharmacist	Katie Ray
Medical Director, CW Emergency	Amy Drendel, DO
Quality Director, Pediatrician, CMG	Chris Schwake, MD

Medical Disclaimer

This Clinical Guideline (CG) is designed to provide a framework for evaluation and treatment. It is not intended to establish a protocol for all patients with this condition, nor is it intended to replace a clinician's judgement. Adherence to this CG is voluntary. Decisions to adopt recommendations from this CG must be made by the clinician in light of available resources and the individual circumstances of the patient. Medicine is a dynamic science; as research and clinical experience enhance and inform the practice of medicine, changes in treatment protocols and drug therapies are required. The authors have checked with sources believed to be reliable in their effort to provide information that is complete and generally in accord with standards accepted at the time of publication. However, because of the possibility of human error and changes in medical science, neither the authors nor Children's Hospital and Health System, Inc., nor any other party involved in the preparation of this work warrant that the information contained in this work is in every respect accurate or complete, and they are not responsible for any errors in, omissions from, or results obtained from the use of this information.